| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Tubulin-IN-55 (Compound 89) (0.1-10 μM, 24 h) showed potent antiproliferative activity against HeLa, HCT116 and 4T1 cells, with IC50 values of 1.20 μM, 4.91 μM, 1.13 μM and 0.65 μM, respectively [1]. Tubulin-IN-55 (0.3-0.9 μM, 12-24 h) showed anti-migration and anti-invasion effects against HeLa, HCT116 and 4T1 cells [1]. Tubulin-IN-55 (0.3-1.2 μM, 24 h) induced apoptosis and G2/M phase arrest in HeLa, HCT116 and 4T1 cells [1]. Tubulin-IN-55 (6.25-100 μM, 60 min) inhibited microtubule polymerization in vitro in a dose-dependent manner [1]. Tubulin-IN-55 (0.3-0.9 μM, 24 h) downregulated the phosphorylation levels of PI3K and Akt in HeLa, HCT116 and 4T1 cells without changing the total levels of PI3K and Akt. Tubulin-IN-55 (0.1-10 μM, 24 h) showed antitumor activity against BC-PDO1, BC-PDO2 and BC-PDO10 (breast cancer organoids), and reduced organoid activity, with IC50 values of 1.07 μM, 0.81 μM and 0.42 μM, respectively [1].
|
|---|---|
| ln Vivo |
Tubulin-IN-55 (compound 89) (10 mg/kg, intraperitoneal injection, every two days for 4 weeks) showed significant antitumor efficacy in an orthotopic autologous transplantation model in BALB/c mice [1].
|
| Cell Assay |
Cell Migration Assay [1]
Cell Types: HeLa, HCT116, and 4T1 cells Tested Concentrations: 0.3, 0.9 μM Incubation Duration: 12, 24 h Experimental Results: Exhibited anti-migratory effects on HeLa, HCT116, and 4T1 cells. Upregulated epithelial marker E-Cadherin. Cell Invasion Assay[1] Cell Types: HeLa, HCT116, and 4T1 cells Tested Concentrations: 0.3, 0.9 μM Incubation Duration: 12, 24 h Experimental Results: Exhibited anti-migratory effects on HeLa, HCT116, and 4T1 cells. Upregulated epithelial marker E-Cadherin. Apoptosis Analysis[1] Cell Types: 0.3, 0.6, 1.2 μM Tested Concentrations: 0.3, 0.9 μM Incubation Duration: 24 h Experimental Results: Induced apoptosis. Increased the proportion of apoptotic cells. Upregulated cleaved-PARP and Bax, and downregulated Bcl-2. Cell Cycle Analysis[1] Cell Types: 0.3, 0.6, 1.2 μM Tested Concentrations: 0.3, 0.9 μM Incubation Duration: 24 h Experimental Results: Induced G2/M phase arrest. Upregulated Cyclin B1 and downregulated CDK1 and Cdc25c. |
| Animal Protocol |
Animal/Disease Models: Tumor cells were implanted into 6-8-week-old BALB/c mice to establish the in vivo tumor model[1]
Doses: 10 mg/kg Route of Administration: i.p., once every two days, 4 weeks Experimental Results: Achieved tumor growth inhibition. Suppressed breast cancer metastasis to the lung. Reduced the Ki67 expression and PCNA expression in tumor tissues. Disrupted the microtubule network in tumor tissues. Showed no significant changes in body weight and major organ (heart, liver, spleen, lung, kidney) weights. |
| References |
| Molecular Formula |
C21H26N4O
|
|---|---|
| Molecular Weight |
350.46
|
| CAS # |
353258-94-3
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8534 mL | 14.2670 mL | 28.5339 mL | |
| 5 mM | 0.5707 mL | 2.8534 mL | 5.7068 mL | |
| 10 mM | 0.2853 mL | 1.4267 mL | 2.8534 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
